Assessment of cytochrome P450 3A4-mediated drug –drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model

ConclusionThis study demonstrates the value of using a fit-for-purpose PBPK model to assess the clinical DDIs for ipatasertib and to provide dosing strategies for the concurrent use of other CYP3A4 perpetrators or victims.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research